Company Analysis
Sign in

PMV Pharmaceuticals, Inc. (PMVP)

Nasdaq: PMVP · Pharmaceutical Preparations · Princeton, NJ · filing with the SEC since 2017
Full chart Alerts Compare
Grade5.9
◀ Past 6.6● Present 6.2▶ Future 5.2
6 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

11 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to PMV Pharmaceuticals, Inc.’s names, not what it holds today.

Patents granted
11
11 utility, 1976 to Dec 31, 2025
Granted in 2025
2
Against 3 in 2024 and 3 in 2023
Applications published
22
1 of them in 2025
Names they are printed under
2
its own name
By yearGrantedApplications published
'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Organic fine chemistry7
Pharmaceuticals2
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name2 counted
PMV Pharmaceuticals, Inc. its own name
named as the applicant on its applications, in US
0 granted
22 published
PMV PHARMACEUTICALS, INC. its own name
US, as the owner printed on each patent
11 granted
0 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Sep 30, 202512,428,406Methods and compounds for restoring mutant p53 functionOrganic fine chemistryPMV PHARMACEUTICALS, INC.
Sep 23, 202512,419,880Companion diagnostic tool for mutant p53 reactivating compoundsPharmaceuticalsPMV PHARMACEUTICALS, INC.
Apr 23, 202411,963,953Deuterated compounds for restoring mutant p53 functionOrganic fine chemistryPMV PHARMACEUTICALS, INC.
Mar 26, 202411,938,124Combination therapy for treatment of cancerPharmaceuticalsPMV PHARMACEUTICALS, INC.
Mar 12, 202411,926,632Methods and compounds for restoring mutant p53 functionOrganic fine chemistryPMV PHARMACEUTICALS, INC.
Nov 14, 202311,814,373Methods and compounds for restoring mutant p53 functionOrganic fine chemistryPMV PHARMACEUTICALS, INC.
Nov 7, 202311,807,644Methods and compounds for restoring mutant p53 functionOrganic fine chemistryPMV PHARMACEUTICALS, INC.
Aug 22, 202311,731,953Methods and compounds for restoring mutant p53 functionOrganic fine chemistryPMV PHARMACEUTICALS, INC.
May 24, 202211,339,141Methods and compounds for restoring mutant p53 functionOrganic fine chemistryPMV PHARMACEUTICALS, INC.
May 5, 202010,640,485Methods and compounds for restoring mutant p53 functionOrganic fine chemistryPMV PHARMACEUTICALS, INC.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Oct 16, 20252025/0319063METHODS AND COMPOUNDS FOR RESTORING MUTANT P53 FUNCTIONPharmaceuticalsPMV Pharmaceuticals, Inc.
Oct 17, 20242024/0342151DEUTERATED COMPOUNDS FOR RESTORING MUTANT p53 FUNCTIONOrganic fine chemistryPMV Pharmaceuticals, Inc.
Aug 15, 20242024/0269126COMBINATION THERAPY FOR TREATMENT OF CANCERPharmaceuticalsPMV Pharmaceuticals, Inc.
Apr 11, 20242024/0116910Heterocycles as WIP1 InhibitorsOrganic fine chemistryPMV Pharmaceuticals, Inc.
Mar 28, 20242024/0100050MDM2 INHIBITORS AND USES THEREOFPharmaceuticalsPMV Pharmaceuticals, Inc.
Feb 8, 20242024/0043436METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTIONOrganic fine chemistryPMV Pharmaceuticals, Inc.
Oct 5, 20232023/0312539METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTIONOrganic fine chemistryPMV Pharmaceuticals, Inc. · patent 12,428,406 granted from it
Sep 28, 20232023/0301975DEUTERATED COMPOUNDS FOR RESTORING MUTANT p53 FUNCTIONOrganic fine chemistryPMV Pharmaceuticals, Inc. · patent 11,963,953 granted from it
Feb 23, 20232023/0056253METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTIONOrganic fine chemistryPMV Pharmaceuticals, Inc. · patent 11,731,953 granted from it
Feb 16, 20232023/0049952METHODS AND COMPOUNDS FOR RESTORING MUTANT P53 FUNCTIONPharmaceuticalsPMV Pharmaceuticals, Inc.
What it applied for, 2024 to 2025: Organic fine chemistry 3 · Pharmaceuticals 3.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton PMVP · research, not advice